The Medical Letter on Drugs and Therapeutics
Deutetrabenazine (Austedo) for Huntington's Chorea and Tardive Dyskinesia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved deutetrabenazine (Austedo – Teva), a vesicular monoamine transporter 2 (VMAT2) inhibitor, for treatment of chorea associated with Huntington's disease and, more recently, for treatment of tardive dyskinesia in adults. It is the second VMAT2 inhibitor to be approved for each of these indications; tetrabenazine (Xenazine, and generics) was approved earlier for Huntington's chorea1 and valbenazine (Ingrezza) was recently approved for treatment of adults with tardive dyskinesia.2

HUNTINGTON'S DISEASE — Huntington's disease is an autosomal dominant, progressive neurodegenerative disorder caused by mutations in the huntingtin (HTT) gene that encodes the huntingtin protein. No available treatment slows progression of the disease, but symptomatic treatment of depression, anxiety, cognitive impairment, ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Deutetrabenazine (Austedo) for Huntington's Chorea and Tardive Dyskinesia
Article code: 1545a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian